Which company produces nirogacestat?
Nirogacestat (nirogacestat) is an oral targeted drug with an innovative mechanism, used to treat progressive desmoid tumors that require systemic intervention. Its original drug development company is the American biopharmaceutical company SpringWorks Therapeutics Inc. The company focuses on the development of highly selective small molecule drugs for rare tumors and molecular targeting pathways, and occupies an important position in the global oncology drug research and development field. SpringWorks was founded in 2017 and was developed with the support of Pfizer's incubation program. It has a strong clinical R&D and commercialization platform and is committed to the research and development of precision medicine and molecular mechanism-driven drugs. Nirogacestat, one of its star products, is the first targeted drug specifically targeting Desmoid tumors. Although this tumor is benign, it is highly invasive and traditional treatments are ineffective. Therefore, the advent of this drug is of great significance.

SpringWorks has advanced Nirogacestat's marketing process through global multi-center clinical trials, and has been granted "Breakthrough Therapy Designation" and "Orphan Drug Designation" by the US FDA, showing that it has obvious advantages in terms of efficacy and clinical needs. It is worth noting that the drug has not yet been approved for marketing in mainland China, so no domestic company has the relevant sales rights. For patients who wish to use the drug, they can currently only obtain the original version through Hong Kong or overseas medical channels. They must go through formal channels to ensure the source and safety of the drug.
In short,Nirogacestat is a γ-secretase inhibitor originally developed by SpringWorks Therapeutics Inc.. Its research and development represents the international advanced level of innovative drugs targeting the Notch pathway and is also one of the important options for the future treatment of Desmoid tumors.
Reference materials:https://www.drugs.com/mtm/nirogacestat.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)